Poseida Therapeutics, Inc.

NASDAQ:PSTX

3.51 (USD) • At close September 18, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

2024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32019 Q22019 Q12018 Q42017 Q4
Revenue 25.97328.14224.9959.35220.01310.3439.921116.3062.71.4350.0310000000000000
Cost of Revenue 1.3491.384.1761.4441.4081.3241.3551.351.261.2070.0311.1691.1281.072103.52000000000
Gross Profit 24.62426.76220.8197.90818.6059.0198.566114.9561.440.2280-1.169-1.128-1.072-103.52000000000
Gross Profit Ratio 0.9480.9510.8330.8460.930.8720.8630.9880.5330.1590.0010000000000000
Reseach & Development Expenses 44.19841.54142.04637.48239.19238.05233.90435.13735.00848.850.03932.52436.00829.0950.02827.01625.2123.41419.20415.69616.8818.6139.7534.354
General & Administrative Expenses 12.1829.7988.868.0928.67611.8079.3689.3899.2379.5460.019.0668.8718.3690.0076.4584.2364.8544.0084.0074.0426.3992.3971.595
Selling & Marketing Expenses 000000000000000000000000
SG&A 12.1829.7988.868.0928.67611.8079.3689.3899.2379.5460.019.0668.8718.3690.0076.4584.2364.8544.0084.0074.0426.3992.3971.595
Other Expenses 2.6442.556-12.0246.7872.542.6972.170.6560.052-0.0190.020.0030.017-0.0120-0.092-0.090.3980.5190.7440.6190.67600
Operating Expenses 56.3851.33950.90645.57447.86849.85943.27244.52644.24558.3960.04941.5944.87937.4640.03533.47429.44628.26823.21219.70320.92315.01212.2554.8
Operating Income -31.756-24.577-25.911-36.222-27.855-39.516-33.22171.78-41.545-56.961-0.017-41.59-44.879-37.464-0.035-33.474-29.446-28.268-23.212-20.763-28.343-13.215-12.15-5.949
Operating Income Ratio -1.223-0.873-1.037-3.873-1.392-3.821-3.3490.617-15.387-39.694-0.560000000000000
Total Other Income Expenses Net 0.3850.3030.5624.5512.540.6690.195-1.119-1.491-1.0960.020.0030.017-0.0120-0.092-0.090.3980.519-0.316-6.8012.473-0.7340.819
Income Before Tax -31.371-24.274-25.349-31.671-27.456-38.847-33.02670.661-43.036-58.0570.001-42.424-45.705-38.314-0.036-34.414-30.428-28.784-23.613-20.954-28.627-13.334-12.884-5.13
Income Before Tax Ratio -1.208-0.863-1.014-3.387-1.372-3.756-3.3290.608-15.939-40.4580.0470000000000000
Income Tax Expense 01.337-6.04-0.1074.6811.3590.2920.2521.4911.096-17.6020.840.860.826-1.0390.7560.8021.3121.4391.6791.5221.4710.0060.339
Net Income -31.371-24.274-23.99-31.778-27.456-40.206-33.31870.409-44.527-59.1530.001-42.424-45.705-38.314-0.036-34.414-30.428-28.784-23.613-20.954-28.627-13.334-12.89-4.791
Net Income Ratio -1.208-0.863-0.96-3.398-1.372-3.887-3.3580.605-16.491-41.2220.0470000000000000
EPS -0.32-0.25-0.27-0.35-0.32-0.47-0.390.92-0.71-0.950.02-0.68-0.74-0.62-0.001-0.63-0.53-0.5-0.59-0.53-0.72-0.34-1.05-0.41
EPS Diluted -0.32-0.25-0.27-0.35-0.32-0.47-0.390.92-0.71-0.950.02-0.68-0.74-0.62-0.001-0.63-0.53-0.5-0.59-0.53-0.72-0.34-1.05-0.41
EBITDA -30.407-23.197-46.183-36.222-23.907-36.819-31.05173.786-40.233-55.7730.002-40.418-43.734-36.404-0.035-32.879-29.093-27.454-22.307-18.612-20.045-14.135-11.997-5.775
EBITDA Ratio -1.171-0.824-1.848-3.873-1.195-3.56-3.130.634-14.901-38.8660.0740000000000000